Agenus

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agenus reports robust Q4 earnings, advances immuno-oncology pipeline

Agenus showcased strong financials, progress in immuno-oncology pipeline, and durable responses in various cancers
Strategic partnerships and innovative R&D capabilities position the company well for future growth and development
Challenges in enrollment, differentiation, and managing immune-related toxicities are being actively addressed for continued success

Agenus (AGEN) reports progress in cancer treatment programs

Agenus (AGEN) showcased strong progress in its cancer treatment programs, with notable response rates and Fast Track Designation for a promising combination therapy.
While financials remained stable, the company faces challenges in maintaining response rates and successful study enrollments, requiring effective regulatory navigation and communication strategies.
Opportunities for Agenus include presenting at ASCO, expanding development programs, and attracting partnerships to drive further advancements in oncology treatments.

Agenus reports positive trial outcomes and strong regulatory strategy

Agenus is making significant progress in cancer treatment with positive trial outcomes and a strong regulatory strategy.
The company's commitment to innovation, patient quality of life, and managing side effects positions them well for future success.
Challenges include addressing analyst inquiries, enrollment in studies, and managing toxicities, but opportunities exist in partnerships and targeted treatment approaches.

Agenus reports robust earnings, eyes strategic partnerships for growth

Agenus Inc. demonstrated strong financial performance and progress in its BOT/BAL program.
While facing challenges in trial enrollment and funding, the company is focused on strategic partnerships.
Opportunities lie in upcoming data disclosures, potential BLA submissions, and product launches.

Agenus reports Q1 2024 financials, progresses BOT/BAL program for growth

Agenus navigates financial challenges with a focus on advancing the BOT/BAL program towards commercialization. Despite losses, the company's strategic initiatives position it for potential growth opportunities through milestone achievements and market expansion.

Agenus (AGEN) reports Q3 loss, advances cancer therapy innovations

Agenus (AGEN) is navigating financial challenges with a focus on advancing transformative cancer therapy and strategic partnerships.
Despite a net loss of $67 million, progress in BOT/BAL development and strategic initiatives position Agenus for future growth.
Opportunities in upcoming clinical studies and data readouts in 2025 underscore the company's commitment to innovation and patient care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Corvus Pharmaceuticals

Liquidia Technologies Inc

PhaseBio Pharmaceuticals Inc

Tonix Pharmaceuticals Hld

Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch For November With Potential Biotech Catalysts

The heavy selling pressure might have exhausted for Agenus (AGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 33.3% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround

Conference Call on Tuesday, November 9, 2021, at 8:30 a.m. ET Conference Call on Tuesday, November 9, 2021, at 8:30 a.m. ET

Agenus to Provide Corporate Update and Third Quarter 2021 Financial Report

Atea Pharmaceuticals

Novavax

Ocular Therapeutix

Biotech stocks that fall hard on bad news can rebound in a flash.

Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy?

The company's experimental anti-PD1 drug hit a wall.

Here's Why Agenus Stock Is Getting Hammered Today

LEXINGTON, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced a strategic decision to withdraw its Biologics License Application (BLA) for balstilimab, its PD-1 inhibitor. The decision to withdraw the BLA does not change the development plans for balstilimab combinations.

Agenus Provides Update on Balstilimab Development

LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific anti-TIGIT antibody. Agenus will receive a $20 million cash payment with the dosing of the first patient.

Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody

GlaxoSmithKline

But those wins probably won't be all that big.

2 Stocks Set to Win From the Historic Malaria Vaccine Approval

LEXINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced acceptance of its abstract describing updated Phase 1 clinical trial results for AGEN1181 (Fc-enhanced anti-CTLA-4) alone and in combination with balstilimab (anti-PD-1) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, to be held November 10-14, 2021.

Agenus to Present AGEN1181 Clinical Data at SITC

Agenus Inc (NASDAQ: AGEN) presented final results from the Bal/Zal combination study at the European Society for Medical Oncology ( ESMO21 ) Virtual Conference 2021. Related:   Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer.

Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer

LEXINGTON, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented final results from the Bal/Zal combination study at the European Society for Medical Oncology (ESMO) Virtual Conference 2021 in an abstract titled Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): final results from a Phase 2 study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC).

Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO

Development of saponin molecules designed to provide high-efficacy and long-lasting protection for pandemic vaccines Development of saponin molecules designed to provide high-efficacy and long-lasting protection for pandemic vaccines

New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks

LEXINGTON, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that results from a global Phase 2 clinical study of balstilimab monotherapy in recurrent/metastatic cervical cancer were published online in the international peer reviewed journal Gynecologic Oncology (https://doi.org/10.1016/j.ygyno.2021.08.018).

Balstilimab Monotherapy Data Published in Gynecologic Oncology

In Q42021 (likely at SITC), AGEN is anticipated to publish updated 1181/Bal Phase 2 clinical data in MSS-CRC that shows 1181/Bal significantly outperforms current FDA approved 3rd line standard-of-care.

Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains

Agenus made a potentially $1.5 billion deal with Bristol Myers in May.

Agenus Multiple Value-Adding Events Ahead

Dynavax Technologies

GT Biopharma Inc

Is it time to add biotech stocks to your list this year? The post Hot Biotech Stocks That Deserve Your Attention In August 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Stocks That Deserve Your Attention In August 2021

Investors were spooked by some ugly numbers in the company's latest earnings report.

Why Agenus Fell by Over 4% on Monday

Agenus' (AGEN) CEO Garo Armen on Q2 2021 Results - Earnings Call Transcript

Agenus (AGEN) delivered earnings and revenue surprises of -54.17% and -36.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Reports Q2 Loss, Misses Revenue Estimates

Shares of Agenus (NASDAQ:AGEN) moved higher by 2.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 32.14% over the past year to ($0.37), which missed the estimate of ($0.24).

Recap: Agenus Q2 Earnings

LEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the second quarter of 2021.

Agenus Corporate Update and Second Quarter 2021 Financial Report

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions. MiNK is a subsidiary of Agenus Inc. (NASDAQ: AGEN).

MiNK Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

A top company executive is stepping down in the very near future.

Why Agenus Stock Sank on Tuesday

Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET

News for Agenus Stock (AGEN)